Yanfei Xin

Yanfei Xin

Auto-generated profile, based on publicly available information

Yanfei Xin

Center of Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
YXYan-Fei Xin
Yan-Fei Xin
LWLi-Li Wan
Li-Li Wan
JPJin-Liang Peng
Jin-Liang Peng
CGCheng Guo
Cheng Guo

10 March 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
THTao Huang
Tao Huang
XCXiaoying Chen
Xiaoying Chen
QHQingxiao Hong
Qingxiao Hong
ZDZaichun Deng
Zaichun Deng
HMHongying Ma
Hongying Ma
QZQiudan Zhang
Qiudan Zhang
Aberrant DNA methylation can be a potential genetic mechanism in non-small cell lung cancer (NSCLC). However, inconsistent findings existed among the recent association studies between cigarette smoking and gene methylation in lung cancer. The purpose of our meta-analysis was to evaluate the role of gene methylation in the smoking behavior of NSCLC patients. A total of 116 genes were obtained from 97 eligible publications in the current meta-analyses. Our results showed that 7 hypermethylated genes (including CDKN2A, RASSF1, MGMT, RARB, DAPK, WIF1 and FHIT) were significantly associated with the smoking behavior in NSCLC patients. The further population-based subgroup meta-analyses showed that the CDKN2A hypermethylation was significantly associated with cigarette smoking in Japanese, Chinese and Americans. In contrast, a significant association of RARB hypermethylation and smoking behavior was only detected in Chinese but not in Japanese. The genes with altered DNA methylation were likely to be potentially useful biomarkers in the early diagnosis of NSCLC.

20 October 2011 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
YXYan‐Fei Xin
Yan‐Fei Xin
ZYZhen‐Qiang You
Zhen‐Qiang You
HGHai‐Yan Gao
Hai‐Yan Gao
GZGuo‐Liang Zhou
Guo‐Liang Zhou
YCYun‐Xiang Chen
Yun‐Xiang Chen
YXYao‐Xian Xuan
Yao‐Xian Xuan

11 July 2007 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
YXYan‐Fei Xin
Yan‐Fei Xin
GZGuo‐Liang Zhou
Guo‐Liang Zhou
ZDZu‐Yue Deng
Zu‐Yue Deng
YCYun‐Xiang Chen
Yun‐Xiang Chen
YWYue‐Guo Wu
Yue‐Guo Wu
YXYao‐Xian Xuan
Yao‐Xian Xuan

1 January 2011 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
YXYanfei Xin
Yanfei Xin
SZSheng Zhang
Sheng Zhang
LGLiqiang Gu
Liqiang Gu
SLShupeng Liu
Shupeng Liu
HGHaiyan Gao
Haiyan Gao
YXYaoxian Xuan
Yaoxian Xuan
Doxorubicin (DOX) is a potent antitumor agent, but the cardiotoxicity mediated by the formation of reactive oxygen species limit its clinical use. The present study aims to explore electrocardiographic and biochemical evidence for the cardioprotective effect of two antioxidants, Lycium barbarum polysaccharides (LBP, the main antioxidant in Lycium barbarum) and edaravone (a potent free radical scavenger, EDA) against DOX-induced acute cardiotoxicity in beagle dogs. In this study, male beagle dogs received daily treatment of either LBP (20 mg/kg, per os (p.o.)) or EDA (2 mg/kg, intravenously (i.v.)) for 7 d and then followed by an intravenous injection of DOX (1.5 mg/kg). DOX (15 mg/kg) significantly induced acute cardiotoxicity in dogs characterized by conduction abnormalities (including decreased heart rate, ST segment elevation, QT intervals prolongation, inverted T wave, arrhythmia, and myocardial ischemia) and increased serum creatine kinase (CK) and aspartate aminotrans-ferase (AST). Pretreatment with LBP or EDA effectively alleviated both DOX-associated conduction abnormalities and increased serum CK and AST. Moreover, physiological and serum biochemical evidences demonstrated that EDA is more effective than LBP in alleviating these abnormalities produced by DOX in heart. All these results confirm and extend previous observations in rats concerning the effectiveness of LBP or EDA against DOX-induced cardiomyopathy.

15 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLina Zhang
Lina Zhang
PLPan-Pan Liu
Pan-Pan Liu
LWLingyan Wang
Lingyan Wang
FYFang Yuan
Fang Yuan
LXLeiting Xu
Leiting Xu
QZQiudan Zhang
Qiudan Zhang
The goal of our study is to investigate the contribution of promoter DNA methylation of α-adducin (ADD1) gene to the risk of essential hypertension (EH). Using the bisulphite pyrosequencing technology, DNA methylation levels of five CpG dinucleotides on ADD1 promoter were measured among 33 EH cases and 28 healthy controls. Significantly higher ADD1 DNA methylation levels were observed in the females than in the males (CpG1: P = 0.016; CpG2-5: P = 0.021). A breakdown analysis by gender showed that lower CpG1 methylation was associated with an increased risk of EH in females (adjusted P = 0.042). A much more significant association between lower CpG2-5 methylation levels and the increased risk of EH was found in males (adjusted P = 0.008). CpG1 methylation was inversely correlated with age in females (r = −0.407, P = 0.019) but not in males. ADD1 CpG1 and CpG2-5 methylation levels were significantly lower in post-menopausal (>50 years) women than pre-menopausal (≤50 years) women (CpG1: P = 0.006; CpG2-5: P = 0.034). A significant interaction between CpG1 methylation and age was found in females (CpG1*age: P = 0.029). CpG2-5 methylation was shown as a significant predictor of EH in males [area under curve (AUC) = 0.855, P = 0.001], in contrast that CpG1 methylation was a trend toward indicator in females (AUC = 0.699, P = 0.054). In addition, significant differences were observed between males and females for alanine aminotransferase (ALT, P = 0.001), aspartate aminotransferase (AST, P = 0.005) and uric acid ( P <0.001). The concentration of AST was inversely correlated with ADD1 CpG2-5 methylation levels in female controls (r = −0.644, P = 0.024). These observations may bring new hints to elaborate the pathogenesis of EH.